Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818 008 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
+44 1494 818 008

Within my time at Zenopa, I have found my Contractor Manager to offer the most fantastic support! The transition from my previous contract house was seamless and all the processes with Zenopa are very...
Jaz, 2012

Bayer HealthCare to publish new regorafenib trial data

16 January 2012 00:00 in Pharmaceutical Company Product News

Bayer HealthCare will be publishing new data from a pivotal phase III trial of its metastatic colorectal cancer treatment regorafenib this month.

The company will attend the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology in order to showcase data from the international study, known as Correct.

A total of 760 patients were enrolled in the trial in order to evaluate the efficacy of regorafenib plus best supportive care among patients whose disease has progressed after standard therapies, compared to placebo.

Bayer already confirmed in October 2011 that the study had met its primary endpoint by offering significant improvement to overall survival rates, allowing the company to continue the study unblinded.

Data from this trial will be used to support regulatory submissions for the drug in 2012.

Regorafenib has been earmarked by its manufacturer as offering potential blockbuster commercial potential once approved, representing one of a number of promising oncology compounds in Bayer's pipeline.ADNFCR-8000103-ID-801265128-ADNFCR

Other news stories from 16/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd